Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) rose 1.1% on Friday, reaching a high of $2.90 and closing at $2.88. The stock had a trading volume of 9,783 shares, a decrease of 76% from the average daily volume. DiaMedica Therapeutics has been the subject of recent analyst reports, with Oppenheimer restating an 'outperform' rating and a $6.00 price target, and Craig Hallum initiating coverage with a 'buy' rating and an $8.00 price target. The company has a market capitalization of $109.34 million and a PE ratio of -5.14. DiaMedica Therapeutics last reported quarterly earnings on March 20th, with an EPS of ($0.14), in line with estimates. Institutional investors own 10.12% of the company's stock. DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on improving the lives of people suffering from serious diseases, with a lead candidate, DM199, in Phase II/III trials for the treatment of acute ischemic stroke.
Hong Kong-based Olympus Capital Asia has sold a 9% stake in hospital chain Aster DM Healthcare for Rs 1,530 crore through open market transactions. The investment firm, through its arm Olympus Capital Asia Investments, sold 4.50 crore shares of Aster DM Healthcare in two tranches at a price range of Rs 340-340.13 apiece. After the transaction, Olympus Capital Asia's shareholding in Aster DM Healthcare has declined to 1.1% from 10.1%. Franklin Templeton Mutual Fund, the Singapore government, and Morgan Stanley Asia Singapore purchased a total of 1.24 crore shares of Aster DM Healthcare at an average price of Rs 340, amounting to Rs 423.31 crore.
Olympus Capital Asia has divested a major stake in Aster DM Healthcare for Rs 1,530 crore. The divestment was made through open market transactions on the Bombay Stock Exchange (BSE), with the shares being sold at a price range of Rs 340-340.13 each. Following the transaction, Olympus Capital Asia's stake in Aster DM Healthcare has decreased from 10.1% to 1.1%. Franklin Templeton Mutual Fund, Morgan Stanley Asia, and the Singapore government acquired a total of 1.24 crore shares of Aster DM Healthcare at an average price of Rs 340, totaling Rs 423.31 crore. This divestment is part of Olympus Capital Asia's strategy to exit its investments in India. Aster DM Healthcare is a healthcare service provider based in India. The sale of the stake will allow Olympus Capital Asia to generate returns on its investment. [560d59cf]